|
시장보고서
상품코드
2024890
면역 조절제 시장 보고서 : 제품별, 용도별, 지역별(2026-2034년)Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2026-2034 |
||||||
세계의 면역 조절제 시장 규모는 2025년에 2,325억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 3,482억 달러에 달하며, 2026-2034년에 CAGR 4.45%로 성장할 것으로 예측하고 있습니다.
면역조절제는 감염, 면역부전 및 항체 전이 이상에 대한 면역반응을 조절하기 위해 사용되는 약제 클래스을 말합니다. 이러한 약제에는 일반적으로 모노클로널 항체, 사이토카인, 레바미솔, 칼메트 게란균(BCG)이 포함됩니다. 암, 천식, 종양, 유전성 혈관성 부종, 천포창, 루푸스, 알레르기, 류마티스 관절염 등 자가면역질환의 치료에 널리 사용되고 있습니다. 현재 많은 의료진은 염증성장질환(IBD) 관리를 위해 생물제제와 같은 다른 약물과 함께 면역조절제를 권장하고 있습니다.
면역조절제 시장 동향:
급속한 도시화, 소득수준의 상승, 가공식품 소비 증가에 따른 사람들의 건강에 해로운 생활습관으로 인해 전 세계에서 만성질환의 유병률이 크게 증가하고 있습니다. 이로 인해 장기 이식의 필요성이 더욱 증가하고 있으며, 장기 이식 수혜자의 유망한 치료제로서 외용 면역조절제에 대한 수요에 긍정적인 영향을 미치고 있습니다. 또한 고령화의 진전과 사고 건수의 증가도 장기부전의 위험을 높이고 있습니다. 그 결과, 많은 정부기관과 민간단체가 장기 기증을 장려하고 있으며, 이는 전 세계 국소면역조절제 판매를 촉진하고 있습니다. 이와 더불어 염증성장질환(IBD) 및 자가면역질환의 유병률 증가도 시장 성장을 촉진하고 있습니다. 면역조절제는 스테로이드의 장기 사용을 줄이고, 재발을 예방하며, 항생제에 반응하지 않는 질환을 치료하기 위한 병용요법으로도 활용되고 있습니다. 또한 플루복사민, 토실리주맙, 렘데시비르와 병용하는 바리시티닙 등 여러 면역조절제가 신종 코로나바이러스 감염증(COVID-19) 입원 환자 치료에 적용되고 있습니다. 이 외에도 현재 여러 제품 후보가 후기 임상 시험 단계에 있습니다. 이들 제품의 개발로 생명을 위협하는 다양한 질환의 치료에 있으며, 면역조절제의 적용 범위가 확대될 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문
- 지금까지 세계 면역조절제 시장은 어떤 추세를 보였으며, 향후 수년간 어떤 추세를 보일 것인가?
- COVID-19는 세계의 면역조절제 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 제품별로 보면 시장 분석은 어떻게 이루어지는가?
- 용도별 시장 현황은?
- 이 산업의 밸류체인에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계의 면역 조절제 시장의 구조는 무엇이며, 주요 업체는 어디인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 면역 조절제 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porters Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSA 26.05.19The global immunomodulators market size reached USD 232.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 348.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.45% during 2026-2034.
Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines , levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).
IMMUNOMODULATORS MARKET TRENDS:
The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Immunosuppressants
- Antibodies
- Calcineurin Inhibitors
- Glucocorticoids
- Antimetabolites
- Others
- Immunostimulants
- Vaccines
- Antibodies
- Others
Breakup by Application:
- Oncology
- Respiratory
- HIV
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global immunomodulators market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global immunomodulators market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global immunomodulators market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Immunomodulators Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Immunosuppressants
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Antibodies
- 6.1.2.2 Calcineurin Inhibitors
- 6.1.2.3 Glucocorticoids
- 6.1.2.4 Antimetabolites
- 6.1.2.5 Others
- 6.1.3 Market Forecast
- 6.2 Immunostimulants
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Vaccines
- 6.2.2.2 Antibodies
- 6.2.2.3 Others
- 6.2.3 Market Forecast
7 Market Breakup by Application
- 7.1 Oncology
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Respiratory
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 HIV
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Amgen Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Biogen Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Bristol-Myers Squibb Company
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Eli Lilly and Company
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 F. Hoffmann-La Roche AG
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 SWOT Analysis
- 13.3.6 Johnson & Johnson
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Merck & Co. Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Novartis AG
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Pfizer Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.1 Amgen Inc.
